Nasus Pharma Ltd. (NSRX) Research

Nasus Pharma Ltd. is a specialized pharmaceutical firm currently advancing through clinical trials. Their primary focus is on developing innovative nasal medications designed to swiftly address critical emergency health situations. These urgent conditions include severe allergic reactions, such as anaphylaxis, and instances of opioid overdose. At the forefront of their product pipeline are two key treatments: NS002, an intranasal epinephrine powder spray engineered to rapidly combat type 1 severe allergies and anaphylaxis; and NS001, a naloxone powder delivered via a nasal spray, intended to reverse the effects of opioid overdose. A core advantage of their methodology is the utilization of a unique powder-based intranasal delivery system, which ensures exceptionally quick absorption of the medication into the bloodstream.

Market snapshot

Symbol
NSRX
Price
$3.07
Day change
-0.32%
Market cap
$26.4M
P/E ratio
-18.15x
52-week range
1.98-9.99
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$22.00

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Adagene Inc. (ADAG)
  • CervoMed Inc. (CRVO)
  • Fortress Biotech, Inc. (FBIO)
  • Gain Therapeutics, Inc. (GANX)
  • Lite Strategy, Inc. (LITS)
  • Nutriband Inc. (NTRB)

Recent insider activity

  • Teleman Dan Benjamin — P-Purchase (2900 shares) on 2026-04-22
  • Teleman Dan Benjamin — P-Purchase (15000 shares) on 2026-03-31
  • Rubin Eyal — trade (40549 shares) on 2026-11-20
  • Silberman David — trade (10000 shares) on 2026-03-11
  • Teleman Dan Benjamin — trade (0 shares) on 2026-03-18

Open Nasus Pharma Ltd. (NSRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.